UBTF::ATXN7L3 gene fusion defines novel B cell precursor ALL subtype with CDX2 expression and need for intensified treatment

Lorenz Bastian; Alina M Hartmann; Thomas Beder; Sonja Hänzelmann; Jan Kässens; Miriam Bultmann; Marc P Hoeppner; Sören Franzenburg; Michael Wittig; Andre Franke; Inga Nagel; Malte Spielmann; Niklas Reimer; Hauke Busch; Stefan Schwartz; Björn Steffen; Andreas Viardot; Konstanze Döhner; Mustafa Kondakci; Gerald Wulf; Knut Wendelin; Andrea Renzelmann; Alexander Kiani; Heiko Trautmann; Martin Neumann; Nicola Gökbuget; Monika Brüggemann; Claudia D Baldus

doi:10.1038/s41375-022-01557-6

UBTF::ATXN7L3 gene fusion defines novel B cell precursor ALL subtype with CDX2 expression and need for intensified treatment

Lorenz Bastian, Alina M Hartmann, Thomas Beder, Sonja Hänzelmann, Jan Kässens, Miriam Bultmann, Marc P Hoeppner, Sören Franzenburg, Michael Wittig, Andre Franke, Inga Nagel, Malte Spielmann, Niklas Reimer, Hauke Busch, Stefan Schwartz, Björn Steffen, Andreas Viardot, Konstanze Döhner, Mustafa Kondakci, Gerald WulfKnut Wendelin, Andrea Renzelmann, Alexander Kiani, Heiko Trautmann, Martin Neumann, Nicola Gökbuget, Monika Brüggemann, Claudia D Baldus

27 Citations (Scopus)

Original language	English
Journal	Leukemia
Volume	36
Issue number	6
Pages (from-to)	1676-1680
Number of pages	5
ISSN	0887-6924
DOIs	https://doi.org/10.1038/s41375-022-01557-6
Publication status	Published - 06.2022

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being
SDG 9 Industry, Innovation, and Infrastructure
SDG 10 Reduced Inequalities

Access to Document

10.1038/s41375-022-01557-6

Cite this

Bastian, L., Hartmann, A. M., Beder, T., Hänzelmann, S., Kässens, J., Bultmann, M., Hoeppner, M. P., Franzenburg, S., Wittig, M., Franke, A., Nagel, I., Spielmann, M., Reimer, N., Busch, H., Schwartz, S., Steffen, B., Viardot, A., Döhner, K., Kondakci, M., ... Baldus, C. D. (2022). UBTF::ATXN7L3 gene fusion defines novel B cell precursor ALL subtype with CDX2 expression and need for intensified treatment. Leukemia, 36(6), 1676-1680. https://doi.org/10.1038/s41375-022-01557-6

@article{cc82c7ce81974ddf8585a170415b23c1,

title = "UBTF::ATXN7L3 gene fusion defines novel B cell precursor ALL subtype with CDX2 expression and need for intensified treatment",

author = "Lorenz Bastian and Hartmann, \{Alina M\} and Thomas Beder and Sonja H{\"a}nzelmann and Jan K{\"a}ssens and Miriam Bultmann and Hoeppner, \{Marc P\} and S{\"o}ren Franzenburg and Michael Wittig and Andre Franke and Inga Nagel and Malte Spielmann and Niklas Reimer and Hauke Busch and Stefan Schwartz and Bj{\"o}rn Steffen and Andreas Viardot and Konstanze D{\"o}hner and Mustafa Kondakci and Gerald Wulf and Knut Wendelin and Andrea Renzelmann and Alexander Kiani and Heiko Trautmann and Martin Neumann and Nicola G{\"o}kbuget and Monika Br{\"u}ggemann and Baldus, \{Claudia D\}",

note = "Funding Information: This study was in part funded by funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) – project number 444949889 (KFO 5010/1 Clinical Research Unit {\textquoteleft}CATCH ALL{\textquoteright} to LB, AH, MPH, MN, MBr, and CDB), Deutsche Jose Carreras Leuk{\"a}mie Stiftung (DJCLS 01R/2016 to LB and CDB). Funding Information: MBr received personal fees from Incyte (advisory board) and Roche Pharma AG, financial support for reference diagnostics from Affimed and Regeneron, grants and personal fees from Amgen (advisory board, speakers bureau, travel support), and personal fees from Janssen (speakers bureau), all outside the submitted work. The remaining authors declare no competing financial interests. None of the remaining authors has a relevant conflict of interest.",

year = "2022",

month = jun,

doi = "10.1038/s41375-022-01557-6",

language = "English",

volume = "36",

pages = "1676--1680",

journal = "Leukemia",

issn = "0887-6924",

publisher = "Springer Nature",

number = "6",

}

Bastian, L, Hartmann, AM, Beder, T, Hänzelmann, S, Kässens, J, Bultmann, M, Hoeppner, MP, Franzenburg, S, Wittig, M, Franke, A, Nagel, I, Spielmann, M, Reimer, N , Busch, H, Schwartz, S, Steffen, B, Viardot, A, Döhner, K, Kondakci, M, Wulf, G, Wendelin, K, Renzelmann, A, Kiani, A, Trautmann, H, Neumann, M, Gökbuget, N, Brüggemann, M & Baldus, CD 2022, 'UBTF::ATXN7L3 gene fusion defines novel B cell precursor ALL subtype with CDX2 expression and need for intensified treatment', Leukemia, vol. 36, no. 6, pp. 1676-1680. https://doi.org/10.1038/s41375-022-01557-6

TY - JOUR

T1 - UBTF::ATXN7L3 gene fusion defines novel B cell precursor ALL subtype with CDX2 expression and need for intensified treatment

AU - Bastian, Lorenz

AU - Hartmann, Alina M

AU - Beder, Thomas

AU - Hänzelmann, Sonja

AU - Kässens, Jan

AU - Bultmann, Miriam

AU - Hoeppner, Marc P

AU - Franzenburg, Sören

AU - Wittig, Michael

AU - Franke, Andre

AU - Nagel, Inga

AU - Spielmann, Malte

AU - Reimer, Niklas

AU - Busch, Hauke

AU - Schwartz, Stefan

AU - Steffen, Björn

AU - Viardot, Andreas

AU - Döhner, Konstanze

AU - Kondakci, Mustafa

AU - Wulf, Gerald

AU - Wendelin, Knut

AU - Renzelmann, Andrea

AU - Kiani, Alexander

AU - Trautmann, Heiko

AU - Neumann, Martin

AU - Gökbuget, Nicola

AU - Brüggemann, Monika

AU - Baldus, Claudia D

N1 - Funding Information: This study was in part funded by funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) – project number 444949889 (KFO 5010/1 Clinical Research Unit ‘CATCH ALL’ to LB, AH, MPH, MN, MBr, and CDB), Deutsche Jose Carreras Leukämie Stiftung (DJCLS 01R/2016 to LB and CDB). Funding Information: MBr received personal fees from Incyte (advisory board) and Roche Pharma AG, financial support for reference diagnostics from Affimed and Regeneron, grants and personal fees from Amgen (advisory board, speakers bureau, travel support), and personal fees from Janssen (speakers bureau), all outside the submitted work. The remaining authors declare no competing financial interests. None of the remaining authors has a relevant conflict of interest.

PY - 2022/6

Y1 - 2022/6

UR - https://www.scopus.com/pages/publications/85127643522

UR - https://www.mendeley.com/catalogue/e6050b32-e7e2-3268-9f31-b9164fe5ed65/

U2 - 10.1038/s41375-022-01557-6

DO - 10.1038/s41375-022-01557-6

M3 - Journal articles

C2 - 35397658

SN - 0887-6924

VL - 36

SP - 1676

EP - 1680

JO - Leukemia

JF - Leukemia

IS - 6

ER -

UBTF::ATXN7L3 gene fusion defines novel B cell precursor ALL subtype with CDX2 expression and need for intensified treatment

UN SDGs

Access to Document

Other files and links

Cite this